Loading
2 treatment settings, 0 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Managed as ductal carcinoma in situ: excision, with radiotherapy and endocrine therapy considered.
The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hot flushes · ATAC, tamoxifen arm, US label (36% with anastrozole) | 41% | - |
| Cataract · ATAC, tamoxifen arm, US label (6% with anastrozole) | 7% | - |
| Venous thromboembolism · ATAC, tamoxifen arm, US label (3% with anastrozole) | 5% | - |
| Endometrial cancer · ATAC, tamoxifen arm, women with an intact uterus, US label (0.2% with anastrozole); NSABP P-1 found 33 versus 14 invasive endometrial cancers with tamoxifen versus placebo | 0.6% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Treated as HR-positive breast cancer.
Pills that block or remove oestrogen signalling, the mainstay of treatment for hormone-driven breast cancer for 50 years.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.